Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type

"Induction therapy: Tislelizumab combined with radiation~* Tislelizumab: 200mg, IV at 3-week intervals combined with radiotherapy.~* Radiotherapy: 400Gy/20 fractions~Maintenance therapy(after termination of combination therapy)~* Tislelizumab: 200mg IV at 3-week intervals for up to 2 years until disease progression or intolerance."